Navigation Links
University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
Date:1/31/2011

BLUE BELL, Pa., Jan. 31, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial (WIN Trial) to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device. This open-label, multi-center clinical trial being run by the University of Southampton is evaluating a DNA vaccine to treat chronic myeloid leukemia and acute myeloid leukemia. Financial support for the trial is being provided by the UK research charity Leukaemia and Lymphoma Research (LLR) and by the Efficacy and Mechanisms Evaluation (EME) programme (which is funded by the UK Medical Research Council and managed by the UK National Institute for Health Research). The DNA vaccine was developed at the University of Southampton with funding from LLR and the charity Cancer Research UK.

(Logo:  http://photos.prnewswire.com/prnh/20110127/LA37605LOGO)

Leukemia is a cancer of the bone marrow and blood that accounts for at least 300,000 new cases and 222,000 deaths worldwide each year - a very high death rate. Wilms' Tumor gene 1 (WT1) is highly associated with these types of cancer, which led the University of Southampton to design its leukemia DNA vaccine to target this antigen. Preclinical data from mice showed strong induction of antigen-specific CD8+ T cells and the ability to kill human tumor cells expressing WT1. There have been several prior clinical studies in humans using parts of the WT1 gene, notably as peptide vaccine candidates, demonstrating the production of modest levels of CD8+ T-cell responses and measurable clinical responses, although both effects were transient. This will be the first study to combine DNA vaccination wit
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
2. Surgeons at University of California San Diego Perform 1st TRAM Flap Procedure in an International Multi-Center Study Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
3. EDC Functionality, Ease of Data Entry, and Access to Data All Factors in University of Virginia Cancer Centers Selection of the OnCore Clinical Research Management System
4. Stereotaxis Announces Global Initial Training Site at University of Chicago
5. SurgiCount Medical Announces the Successful Implementation of the Safety-Sponge® System at the University of Michigan Health System
6. Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco
7. The University of Tennessee Medical Center and ContinuumRx Form Healthcare Joint Venture
8. D3 Radiation Oncology Solutions has Completed Collaborative Commissioning of Two Varian TrueBeam Medical Linear Accelerators at the John Theurer Cancer Center, Hackensack University Medical Center
9. Novus Scientific and Singapore Association of Plastic Surgeons (SAPS) Host the Inaugural Event of SOFTISSUE - The Issue of Soft Tissue, Featuring James J. Chao, M.D., FACS, Professor of Plastic Surgery and Orthopedic Surgery, University of Califor
10. Columbia University Students Learn About Pharmacy Benefit Management From Prime Therapeutics President and CEO
11. Siemens Wins $25 Million Contract From Rush University Medical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... , June 29, 2015  Isis Pharmaceuticals, Inc. (NASDAQ: ... added to the Russell 1000 Index, effective June 26, ... the large-cap segment of the U.S. equity universe. It ... includes approximately 1000 of the largest securities based on ... membership. "We are pleased to be added ...
(Date:6/29/2015)... Axxess , an industry leader in ... vendor accredited by the American Nursing Credentialing Center – ... agencies select the right revenue cycle management (RCM) system ... business. Research by American Health Information Management ... a decrease in productivity of 54.4 - 69 percent ...
(Date:6/29/2015)... 29, 2015  Arbor Solution has added another ... high-powered, multi-functional M2150 offers two platforms: ... Core i5-4402E 1.6 GHz processor and i5-4422E ... and computing performance. Integrated Intel® HD Graphics 4600 ... suited for graphics-intense applications in operating rooms, clinical ...
Breaking Medicine Technology:ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 2ISIS Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index 3Axxess Releases eGuide for Home Health Agencies, Revenue Cycle Management: What You Must Do Now - to Succeed! 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 2Arbor Solution Introduces Multi-Function Medical Workstation with Large 21.5" True Flat Touch Screen 3
... N.J., July 05, 2007 /PRNewswire/ -- Results ... open-label, Phase,3 study showed that 77 percent ... 600 mg tablets with,100 mg ritonavir (PREZISTA/r) ... of antiretroviral (ARV) agents, reached a,plasma viral ...
... 2007 - ZIOPHARM,Oncology, Inc. (NASDAQ: ZIOP) announces ... II trial of ZIO-201 (isophosphoramide mustard,- IPM) ... at the,European Society of Medical Oncology (ESMO) ... The abstract entitled, "Phase-I/II,Study of IPM (ZIO-201) ...
Cached Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 2Positive ZIO-201 Interim Phase II Sarcoma Data Presented at,European Society for Medical Oncology 3
(Date:6/29/2015)... ... 29, 2015 , ... San Fernando Valley skin doctor , Dr. Peyman ... is a special treatment that offers a way to firm sagging facial and neck ... production. Ulthera is highly targeted and precise to help reduce treatment time and improve ...
(Date:6/29/2015)... ... June 29, 2015 , ... The world’s fastest and highest ... Museum to the Science Museum of Virginia. This iconic, supersonic stealth plane will become ... “Suspending a supersonic jet from the ceiling of a historic train station is perhaps ...
(Date:6/29/2015)... ... June 29, 2015 , ... Bionops Laboratories has released the ... French consumers. , The specialized eye health formulation contains a variety of ingredients ... In addition to Citicoline (Cognizin®), Biomacula provides necessary doses of Vitamin E, Glutathione, ...
(Date:6/29/2015)... ... June 29, 2015 , ... Celebrities have many skincare secrets, and ... skin all summer long and beyond. People don’t have to be famous to ... aging process, maintain an even skin tone, avoid breakouts, and take skin health and ...
(Date:6/29/2015)... ... 29, 2015 , ... Blue Cross and Blue Shield of ... Markets division, which includes the company’s commercial health plan portfolio of products and ... and international reach. Mary Ellen Anderson now holds the title of vice president, ...
Breaking Medicine News(10 mins):Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 2Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 3Health News:SR-71 Prepares for Flight to Science Museum of Virginia 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 3Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 2Health News:Skin Guru Shares Celebrity FACE Secrets For Summer-Proofing The Skin 3Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 2Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 3
... The level of interest toddlers with early signs of autism ... to a parent-guided treatment program, a new study suggests. ... age 2 who met the criteria for autism disorders. The ... control group) or enrolled in the Hanen,s More Than Words ...
... University Research Chair Peter Shizgal who investigates the ... been recognized by his peers with the prestigious Prix ... of Psychology and a member of the Centre for ... Socit qubcoise pour la recherche en psychologie (Quebec Society ...
... (HealthDay News) -- Children with epilepsy are at increased risk ... the types of psychiatric problems they develop, a new study ... aged 8 to 13, and found that 111 children (0.8 ... a much higher rate of psychiatric symptoms (38 percent) than ...
... , FRIDAY, March 25 (HealthDay News) -- A poor ... among postmenopausal women, a new study has found. Researchers ... and found that deficiencies in more than a single nutrient ... anemia. Risk increased 44 percent with deficiencies in three nutrients. ...
... Association for Cancer Research is awarding 50 Minority Scholar ... Meeting 2011, held April 2-6. The award, now in ... and training of minority researchers and increase the visibility ... provides funds for the participation of early-career, meritorious minority ...
... Fla. The AACR would like to congratulate its ... 2011, held April 2-6. Grant details and recipients ... AACR-Amgen, Inc. Fellowships in Clinical/Translational Cancer Research , Takashi ... targets in invasive bladder cancer, Kun Wang, Ph.D., University ...
Cached Medicine News:Health News:Interest in Toys May Predict Success of Autism Home Therapy 2Health News:Peter Shizgal distinguished by his peers 2Health News:Gender May Play Role in Psych Symptoms in Kids With Epilepsy 2Health News:Poor Eating Habits May Lead to Anemia in Older Women 2Health News:AACR awards 50 minority scholar in cancer research awards 2Health News:AACR awards 50 minority scholar in cancer research awards 3Health News:AACR awards 50 minority scholar in cancer research awards 4Health News:AACR awards 50 minority scholar in cancer research awards 5Health News:AACR awards 50 minority scholar in cancer research awards 6Health News:AACR awards 50 minority scholar in cancer research awards 7Health News:AACR recognizes its newest grantees at 102nd Annual Meeting 2011 2
Nordan tying forceps, straight, titanium, 6.5 mm tying platforms....
Harms-Tuebingen tying forceps, straight, 6 mm tying platforms....
Castroviejo straight tying forceps, straight shafts, 5 mm tying platforms, wide handle....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Medicine Products: